<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03593681</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN 0507</org_study_id>
    <nct_id>NCT03593681</nct_id>
  </id_info>
  <brief_title>Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy</brief_title>
  <acronym>nCYT</acronym>
  <official_title>The nCYT Study: A Powered Study to Evaluate the Sensitivity and Specificity of Cytological Evaluation of Fallopian Tube Samples Collected by the Cytuity in Determining the Presence of Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, non-randomized study to assess the ability of the Cytuity device
      to collect cell samples from the fallopian tube that can be evaluated for the presence or
      absence of malignancy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Actual">February 14, 2020</completion_date>
  <primary_completion_date type="Actual">February 14, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and Specificity</measure>
    <time_frame>Two weeks after receiving pathology report from clinical site</time_frame>
    <description>Evaluate the sensitivity and specificity of the cytological samples collected from the fallopian tube in determining the presence or absence of malignancy for fallopian tube involvement as compared to the surgical histology results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy for Fallopian Tube Involvement</measure>
    <time_frame>Two weeks after receiving pathology report from clinical site</time_frame>
    <description>Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology of the ovaries and fallopian tube for fallopian tube involvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy of the Fallopian Tube</measure>
    <time_frame>Two weeks after receiving pathology report from clinical site</time_frame>
    <description>Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology of the fallopian tube.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy of the Ovaries</measure>
    <time_frame>Two weeks after receiving pathology report from clinical site</time_frame>
    <description>Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology of the ovaries for epithelial malignancies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy for Subject Level Analysis</measure>
    <time_frame>Two weeks after receiving pathology report from clinical site</time_frame>
    <description>Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and Diagnostic Accuracy will be calculated for Cytuity as compared to surgical histology for fallopian tube involvement subject level analysis.</description>
  </secondary_outcome>
  <enrollment type="Actual">150</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Ovary Cancer</condition>
  <condition>Fallopian Tube Neoplasms</condition>
  <condition>Fallopian Tube Adenocarcinoma</condition>
  <condition>High Grade Serous Carcinoma</condition>
  <condition>Peritoneal Carcinoma</condition>
  <condition>Peritoneal Neoplasms</condition>
  <condition>Adnexal Mass</condition>
  <condition>Ovarian Diseases</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hysteroscopic cell sampling of the fallopian tube</intervention_name>
    <description>Hysteroscopic fallopian tube biopsy</description>
    <other_name>Cytuity</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue and Cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who are scheduled to undergo a salpingo-oophorectomy or salpingectomy because of a
        pelvic mass suspicious for malignancy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is medically cleared for surgery

          2. Subject is scheduled to undergo salpingo-oophorectomy or salpingectomy for a pelvic
             mass suspicious for malignancy

          3. Subject must be 18 years of age

          4. Subject must be able to provide informed consent

        Exclusion Criteria:

          1. Contraindication to hysteroscopy

          2. Acute pelvic inflammatory disease

          3. Active or recent lower pelvic infection

          4. Pregnancy

          5. Delivery or termination of a pregnancy in the past 6 weeks

          6. Known tubal obstruction

          7. Tubal ligation

          8. Invasive carcinoma of the cervix or endometrium

          9. Intolerance of anesthesia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ted L Anderson, MD,PhD,FACOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Clinic Medical Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Health Services</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>salpingo-oophorectomy</keyword>
  <keyword>salpingectomy</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>high grade serous carcinoma</keyword>
  <keyword>hysteroscopic biopsy</keyword>
  <keyword>fallopian tube cell collection</keyword>
  <keyword>peritoneal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Ovarian Diseases</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

